The Role of Artificial Intelligence in Early Phase Clinical Trial Management
In the ever-evolving realm of clinical research, the integration of Artificial Intelligence (AI) is ushering in a new era of efficiency and precision, particularly in the critical domain of Bioavailability/Bioequivalence (BA/BE) studies and early-phase trial management. As the demands for speed, accuracy, and data-driven decision-making escalate, AI emerges as a transformative force, reshaping the landscape of drug development.